Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

Abstract

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.

Effect of NADPH oxidase 1 and 4 blockade in activated human retinal endothelial cells

“…Thus, the first biological drugs to be applied successfully to the treatment of retinal vasculopathy block the action of VEGF. [8][9][10] Other biologically targeted pharmaceuticals are at various stages in the development pipeline, including drugs that directly target the production of ROS. 11 ROS include radicals and non-radicals: superoxide, hydrogen peroxide, hydroxyl radical, peroxynitrite and hypochlorous acid.…”

Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment

“…26,29,30 The Cochrane meta-analysis included 4 RCTs in which bevacizumab therapy and laser surgery were compared for type 1 ROP. 2,5,[31][32][33] The unknown long-term systemic adverse effects of the drug and insufficient data were thought to preclude strong conclusions favoring routine use of intravitreal anti-VEGF agents in preterm infants with ROP. 31 Bevacizumab was not associated with a reduction in the risk of retinal 32 In the current study, we were the first to observe that mortality through infancy was significantly higher in the bevacizumab group compared with the ROP surgery group.…”

“…2,5,[31][32][33] The unknown long-term systemic adverse effects of the drug and insufficient data were thought to preclude strong conclusions favoring routine use of intravitreal anti-VEGF agents in preterm infants with ROP. 31 Bevacizumab was not associated with a reduction in the risk of retinal 32 In the current study, we were the first to observe that mortality through infancy was significantly higher in the bevacizumab group compared with the ROP surgery group. These findings are confounded by baseline differences between the groups and the longer receipt of ventilatory support and supplemental oxygen in infants treated with bevacizumab, although BPD rates were similar.…”

“…15,37 The Canadian Neonatal Network included 125 preterm infants born at ,29 weeks' GA who were treated with bevacizumab (n = 27; mean birth weight 739 g) or laser therapy (n = 98; mean birth weight 714 g); the follow-up rate was 72%, and mortality was 1.7%. 15 Infants in the bevacizumab therapy group had a higher median (IQR) Score for Neonatal Acute Physiology-II score (24 [19][20][21][22][23][24][25][26][27][28][29][30][31] vs 19 [13-28]; P = .03) and more severe ROP compared with infants in the laser surgery group. Infants treated with bevacizumab had lower adjusted motor scores at 18 to 22 months' corrected age.…”

An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model

“…Previous studies indicated that anti-VEGF agents can inhibit ocular neovascularization through intravitreal injections [ 6 – 9 ]. Bevacizumab and ranibizumab have been reported to decrease optic disc edema or to have an anti-inflammatory and anti-neovascular effect on neovascular age-related macular degeneration [ 6 – 8 ].…”